Published in BJU Int on December 20, 2006
Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol (2007) 1.79
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy. Rev Urol (2009) 0.84
Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol (2009) 0.84
Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol (2008) 0.82
Maximizing the treatment of overactive bladder in the elderly. Rev Urol (2008) 0.79
Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract (2007) 0.79
Perspectives on overactive bladder in the elderly population. World J Urol (2009) 0.77
The evolution of transdermal/ topical overactive bladder therapy and its benefits over oral therapy. Rev Obstet Gynecol (2009) 0.77
Development of oxybutynin chloride topical gel for overactive bladder. Open Access J Urol (2011) 0.75
Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder. Res Rep Urol (2012) 0.75
Using the Jigsaw Technique to Teach Clinical Controversy in a Clinical Skills Course. Am J Pharm Educ (2015) 0.75
Oxybutynin topical gel in the treatment of overactive bladder. Open Access J Urol (2010) 0.75
An update on the use of transdermal oxybutynin in the management of overactive bladder disorder. Ther Adv Urol (2016) 0.75
Patient perspectives in the management of overactive bladder, focus on transdermal oxybutynin. Patient Prefer Adherence (2008) 0.75
Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol (2006) 7.13
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2003) 3.82
Time to rethink: an evidence-based response from pelvic surgeons to the FDA Safety Communication: "UPDATE on Serious Complications Associated with Transvaginal Placement of Surgical Mesh for Pelvic Organ Prolapse". Int Urogynecol J (2011) 3.62
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol (2008) 2.72
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol (2007) 2.62
Contemporary management of the painful bladder: a systematic review. Eur Urol (2011) 2.39
The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn (2012) 1.82
Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol (2011) 1.65
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol (2005) 1.47
Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int (2013) 1.47
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol (2012) 1.46
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leuk Res (2011) 1.44
Fesoterodine dose response in subjects with overactive bladder syndrome. Urology (2008) 1.41
Application drying time for oxybutynin chloride topical gel. Urol Nurs (2013) 1.39
Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn (2009) 1.37
Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist (2007) 1.36
Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn (2009) 1.30
The economic impact of overactive bladder syndrome in six Western countries. BJU Int (2009) 1.29
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol (2007) 1.21
Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies. BJU Int (2005) 1.18
Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. Med Decis Making (2007) 1.16
Staying at the cutting edge: a review and analysis of evidence reporting and grading; the recommendations of the American Urological Association. BJU Int (2009) 1.13
Quantifying vaginal tissue elasticity under normal and prolapse conditions by tactile imaging. Int Urogynecol J (2011) 1.11
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther (2008) 1.10
Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol (2004) 1.08
A review of adherence to drug therapy in patients with overactive bladder. BJU Int (2008) 1.06
The current and future burden and cost of overactive bladder in five European countries. Eur Urol (2006) 1.06
Prospective clinical assessment of the transvaginal mesh technique for treatment of pelvic organ prolapse-5-year results. Female Pelvic Med Reconstr Surg (2011) 1.05
Stress incontinence injection therapy: what is best for our patients? Eur Urol (2005) 1.00
Overactive bladder syndrome in older people. BJU Int (2007) 0.99
Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk. BJU Int (2007) 0.98
Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology (2006) 0.98
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
A review of solifenacin in the treatment of urinary incontinence. Ther Clin Risk Manag (2008) 0.98
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron. Am J Hematol (2012) 0.95
Pathophysiology of overactive bladder. Am J Med (2006) 0.94
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology (2006) 0.94
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology (2013) 0.93
Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects. Pharmacotherapy (2004) 0.93
Patient reported outcomes: the ICIQ and the state of the art. Neurourol Urodyn (2010) 0.92
Interventions for detrusor overactivity: the case for multimodal therapy. Rev Urol (2002) 0.92
Interventions and outcomes. What is important (and what is not)? J Urol (2004) 0.92
Symptom severity and QOL scales for urinary incontinence. Gastroenterology (2004) 0.92
Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients. Clin J Am Soc Nephrol (2007) 0.89
Impact of overactive bladder on work productivity. Urology (2012) 0.89
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn (2013) 0.87
Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder. Int Urogynecol J (2014) 0.87
Quality of life and surgical satisfaction after vaginal reconstructive vs obliterative surgery for the treatment of advanced pelvic organ prolapse. Am J Obstet Gynecol (2008) 0.86
What are the best outcome measures when assessing treatments for LUTD?--achieving the most out of outcome evaluation: ICI-RS 2011. Neurourol Urodyn (2012) 0.86
Proteinuria induced by parenteral iron in chronic kidney disease--a comparative randomized controlled trial. Clin J Am Soc Nephrol (2010) 0.86
Positive symptom improvement with laparoscopic uterosacral ligament repair for uterine or vaginal vault prolapse: interim results from an active multicenter trial. J Minim Invasive Gynecol (2007) 0.86
A preliminary evaluation of the TOPAS system for the treatment of fecal incontinence in women. Female Pelvic Med Reconstr Surg (2014) 0.85
Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Postgrad Med (2011) 0.85
Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2005) 0.85
Nocturia research: current status and future perspectives. Neurourol Urodyn (2010) 0.85
Redefining response in overactive bladder syndrome. BJU Int (2007) 0.84
Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role? Semin Dial (2008) 0.84
Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. Pharmacoeconomics (2007) 0.84
Obesity and female stress urinary incontinence. Urology (2013) 0.84
The effects of a continence program on frail community-dwelling elderly persons. Urol Nurs (2003) 0.84
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn (2011) 0.84
Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int (2006) 0.83
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol (2006) 0.83
Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clin Ther (2013) 0.83
Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol (2005) 0.83
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes. Ann Pharmacother (2007) 0.83
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int (2006) 0.82
The nephrologist as a primary care provider for the hemodialysis patient. Int Urol Nephrol (2005) 0.82
The impact of OAB on physical activity in the United States: results from OAB-POLL. Urology (2013) 0.82
Mixed incontinence: current evidence and future perspectives. Neurourol Urodyn (2010) 0.81
Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US. Patient (2011) 0.81
Management of incontinence for family practice physicians. Am J Med (2006) 0.81
Nocturia: new directions. Neurourol Urodyn (2011) 0.81
Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig (2012) 0.80
Laparoscopic nephroureterectomy for adult incontinence caused by functioning ectopic pelvic kidney draining into vagina. J Endourol (2004) 0.79
Urodynamic standardization in a large-scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourol Urodyn (2010) 0.79
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics (2009) 0.79
Reviewing the ICS 2002 terminology report: The ongoing debate. Neurourol Urodyn (2006) 0.78
Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int (2008) 0.78
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Neurourol Urodyn (2008) 0.78
Health care reform 2010: a fresh view on tort reform. J Urol (2010) 0.78
On syndromes, symptoms, and root cause. Eur Urol (2008) 0.77
Radiofrequency for the treatment of stress urinary incontinence in women. Curr Urol Rep (2009) 0.77
Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant (2004) 0.76
Bladder function after radical hysterectomy for cervical cancer. Neurourol Urodyn (2014) 0.76
Bladder sensations during filling cystometry are different according to urodynamic diagnosis. Neurourol Urodyn (2009) 0.75
ACP Journal Club. Review: drugs for urgency urinary incontinence improve continence in women. Ann Intern Med (2012) 0.75
On data sets, extrapolations, and urologic issues. Eur Urol (2010) 0.75
Surgical outcomes reporting--closer to reality. Eur Urol (2007) 0.75
Editorial comment on: Correction of erosion after suburethral sling insertion for stress incontinence: results and related sexual function. Eur Urol (2008) 0.75
Neuromodulation and the urinary tract--are we over the rainbow or have we simply stepped through the looking glass? J Urol (2007) 0.75
Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Eur Urol (2008) 0.75
Editorial comment. Do women with pure stress urinary incontinence need urodynamics? Urology (2009) 0.75
Symptoms, bother, and treatment-seeking behaviors. Eur Urol (2009) 0.75
Editorial. Neurourol Urodyn (2017) 0.75
In memory of Rodney A. Appell (1948-2009). Urology (2009) 0.75